Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer of unknown primary

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    280 result(s) found for: Cancer of unknown primary. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-004562-33 Sponsor Protocol Number: CheCUP Start Date*: 2019-12-04
    Sponsor Name:University Heidelberg, Med. Fac. repr. by University Hospital and its Commercial Managing Director
    Full Title: A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or ...
    Medical condition: Cancer of unknown primary site (CUP-Syndrome), relapsed/refractory to platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007460 Carcinoma of unknown primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005865-67 Sponsor Protocol Number: PXD101-CLN17 Start Date*: 2008-12-11
    Sponsor Name:Topotarget A/S
    Full Title: An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated c...
    Medical condition: Patients with previously untreated carcinoma of unknown primary
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003174-18 Sponsor Protocol Number: PACET-CUP Start Date*: 2009-12-18
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated ...
    Medical condition: adeno- and undifferentiated Carcinoma of Unknown Primary (CUP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001661-32 Sponsor Protocol Number: VeTo Start Date*: 2012-07-05
    Sponsor Name:Vejle Hospital, Dept. of Oncology
    Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status
    Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003040-20 Sponsor Protocol Number: MX39795 Start Date*: 2018-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemoth...
    Medical condition: Cancer of Unknown Primary Site
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10032248 Other malignant neoplasm of unspecified site LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) EE (Completed) IE (Completed) DE (Completed) CZ (Completed) FI (Completed) LV (Completed) HU (Completed) PL (Completed) FR (Completed) ES (Ongoing) BG (Completed) PT (Completed) HR (Completed) NO (Completed) NL (Completed) DK (Completed) CY (Prematurely Ended) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005481-18 Sponsor Protocol Number: BNT142-01 Start Date*: 2022-04-28
    Sponsor Name:BioNTech SE
    Full Title: First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced sol...
    Medical condition: Claudin 6 (CLDN6)-positive advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043302 Testicular cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001912-38 Sponsor Protocol Number: ACR-CMOD / 2005-2 Start Date*: 2006-01-11
    Sponsor Name:ACROSS
    Full Title: PHASE II TRIAL OF THE COMBINATION OF GEMCITABINE AND OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE Estudio fase II de la combinación de gemcitabina...
    Medical condition: METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005018-47 Sponsor Protocol Number: 008-IRCC-10IIS-14 Start Date*: 2015-04-08
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial
    Medical condition: Cancers of Unknown Primary (CUP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073059 Malignant neoplasm of unknown primary site PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004247-23 Sponsor Protocol Number: LUMC201811 Start Date*: 2019-03-22
    Sponsor Name:Leiden University Medical Center
    Full Title: [89Zr]trastuzumab PET/CT imaging of HER2 positive breast cancer for predicting pathologic complete response after neoadjuvant chemotherapy; A multicentre study
    Medical condition: HER2+ breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003522-86 Sponsor Protocol Number: P18.210 Start Date*: 2019-03-21
    Sponsor Name:Leiden University Medical Center
    Full Title: Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer.
    Medical condition: Patient suffering from colorectal or pancreatic adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004163-12 Sponsor Protocol Number: RP2017-001 Start Date*: 2018-01-28
    Sponsor Name:ReposPharma
    Full Title: A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin
    Medical condition: Squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10017985 Gastrointestinal neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003707-18 Sponsor Protocol Number: Evelien05 Start Date*: 2014-04-22
    Sponsor Name:
    Full Title: Absorption of sublingual delivered fentanyl (Abstral®) in head and neck cancer patients treated with curatively aimed chemo-radiotherapy
    Medical condition: head and neck cancer patients treated with chemo-radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004323-20 Sponsor Protocol Number: BNT211-01 Start Date*: 2020-06-30
    Sponsor Name:BioNTech Cell & Gene Therapies GmbH
    Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-...
    Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043302 Testicular cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046766 Uterine cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001207-42 Sponsor Protocol Number: CONFERMER Start Date*: 2014-06-03
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI PARMA
    Full Title: Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown
    Medical condition: Third-line treatment in patients with non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004321-83 Sponsor Protocol Number: GEFCAPI04 Start Date*: 2014-01-27
    Sponsor Name:Institut Català d'Oncologia (ICO)
    Full Title: A randomised phase III trial comparing a strategy based on molecular analysis to the empiric strategy in patients with carcinoma of an unknoun primary (CUP)
    Medical condition: Carcinomas of an unknown primary site (CUP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000206-18 Sponsor Protocol Number: PM1183-B-005-14-QT Start Date*: 2015-09-10
    Sponsor Name:PharmaMar S.A., Sociedad Unipersonal
    Full Title: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors
    Medical condition: - small cell lung cancer (SCLC) - head and neck carcinoma (H&N) - neuroendocrine tumors (NETs) - biliary tract carcinoma - endometrial carcinoma - BRCA 1/2-associated metastatic breast carcinoma - ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019821-32 Sponsor Protocol Number: 20090508 Start Date*: 2010-11-04
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fa...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) PT (Completed) CZ (Prematurely Ended) SI (Completed) GR (Completed) SE (Completed) LV (Completed) EE (Completed) IT (Completed) BG (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017946-30 Sponsor Protocol Number: 20060517 Start Date*: 2011-01-19
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022902-41 Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g Start Date*: 2011-09-26
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa...
    Medical condition: Patients with operable HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) FR (Completed) IE (Completed) SE (Completed) DK (Completed) SI (Completed) NL (Completed) BE (Completed) SK (Completed) AT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-001641-40 Sponsor Protocol Number: ESR-17-12933 Start Date*: 2019-09-09
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Induction Durvalumab (MEDI4736) & Radiotherapy (RT) for Locally Advanced but Resectable Head and Neck Squamous Cell Carcinomas: A Pilot Study
    Medical condition: Advanced resectable head and neck tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 19:16:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA